Streetbeat News

Regulatory

MGTX

MeiraGTx plans to present an update on its AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia on June 27, 2023. The Phase 1 AQUAx clinical trial aims to evaluate the safety of the investigational gene therapy in patients who have remained cancer-free for at least five years.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 8:03 pm

ERAS

Erasca's ERAS-801 has been granted FDA Orphan Drug Designation for the treatment of malignant glioma, including glioblastoma. The drug has also received FDA Fast Track Designation. Initial Phase 1 monotherapy data from the THUNDERBBOLT-1 trial is expected in H2 2023.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 8:02 pm

ETAO

Etao International received a bid price deficiency letter from Nasdaq, notifying the company that it no longer meets the minimum bid price requirement of $1 per share. The company has 180 days to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 7:57 pm

BRK

BTCUSD

Bitcoin has surged past $30,000, approaching its 2023 highs, driven by fresh spot Bitcoin ETF applications from major Wall Street firms like Blackrock, WisdomTree, and Invesco. The cryptocurrency has gained nearly 100% since its 2022 lows.

Portfolio Pulse from Piero Cingari

June 22, 2023 | 7:54 pm

FITB

HBAN

MTB

TROW

USB

Banking and financial stocks are trading lower due to a potential push for increased capital requirements. Fed Chair Powell stated that new rules would likely not impact smaller banks.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 7:44 pm

LFLY

UBER

Leafly (NASDAQ:LFLY) CEO Yoko Miyashita discussed the challenges of moving cannabis consumers from unlicensed to legal markets at the Benzinga Cannabis Capital Conference. Leafly recently partnered with Uber (NYSE:UBER) to launch cannabis delivery services in Canada, leveraging existing infrastructures to meet customer demands.

Portfolio Pulse from Javier Hasse

June 22, 2023 | 7:34 pm

ATVI

MSFT

SONY

Sony Interactive Entertainment CEO Jim Ryan expressed concerns about Microsoft's proposed acquisition of Activision Blizzard, stating that Sony could not risk sharing PlayStation 6 details with Activision if the buyout goes through. Ryan's remarks were made during a hearing with the U.S. Federal Trade Commission in April.

Portfolio Pulse from Franca Quarneti

June 22, 2023 | 7:21 pm

XEL

BMO Capital Markets analyst James M. Thalacker downgraded Xcel Energy Inc (NASDAQ:XEL) from Outperform to Market Perform and decreased the price target to $64 from $69 due to concerns over the lower-than-expected terms of the regulatory settlement in Colorado.

Portfolio Pulse from Lekha Gupta

June 22, 2023 | 6:58 pm

SRPT

The FDA has granted accelerated approval to Sarepta Therapeutics' gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4-5 years with a confirmed mutation in the DMD gene. Continued approval depends on further verification and description of clinical benefit in confirmatory trials. Sarepta is preparing to launch Elevidys and plans to submit a BLA supplement to expand the approved label based on the results of the confirmatory trial.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 6:48 pm

SRPT

Sarepta Therapeutics has received FDA approval for ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. The one-time treatment is approved for ambulatory pediatric patients aged 4-5 years. Sarepta will host a conference call on June 22 at 4:30 p.m. ET.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:03 pm